UNSPSC 51323109: Xenyhexenic acid

This classification denotes an anti-lipidemic agent with the molecular formula C18H18O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4293LHY68W, chemically known as 4-hexenoic acid, 2-(4-biphenylyl)- but generally known as xenyhexenic acid, which bears US NIH Compound Identifier 6436176. European Medicines Agency schedules Xenyhexenic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00107MIG.

UNSPSC 51323109 Xenyhexenic acid (Commodity) does not align with the recent state and local contract opportunities posted under this code. The three most recent opportunities—a Tampa Fire Rescue medication supply bid, a Texas HHS pharmacy benefit program RFI, and a Minnesota cooperative purchasing agreement for generic pharmaceuticals and OTC products—all concern emergency life support medications, prescription fulfillment programs, and generic pharmaceutical distribution rather than xenyhexenic acid specifically. State and local purchasing offices appear to be using this code to tag pharmaceutical procurement more broadly, creating a mismatch between the code's nominal scope and actual buying activity. The opportunities reflect demand from municipal fire departments, state health agencies, and multistate cooperative purchasing alliances for medications including labetalol, epinephrine, adenosine, and diltiazem, as well as infrastructure to manage prescription fulfillment and generic drug sourcing through authorized wholesalers.

The code shows sparse documented activity aligned to xenyhexenic acid itself. The City of Tampa's Bid No. 26P00188 for Advanced Life Support Medications (IFB, due April 8, 2026, estimated value $40,000.00) targets specific emergency pharmaceuticals for Tampa Fire Rescue in Hillsborough County, Florida with a one-year contract term and renewal options. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (due March 26, 2026) establishes multistate contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with effectiveness July 1, 2026. The Texas Health and Human Services Commission's RFI (HHS0017013, posted April 3, 2026) seeks vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager relationships. Activity appears concentrated in municipal emergency services procurement (Florida), state health program administration (Texas), and multistate cooperative purchasing structures (Minnesota and Oregon), though the code's actual scope relative to xenyhexenic acid remains unclear from available solicitation detail.